Titlebook: Quinolone Antibacterials; J. Kuhlmann,A. Dalhoff,H.-J. Zeiler Book 1998 Springer-Verlag Berlin Heidelberg 1998 Chinolon (Gyrasehemmer).DNA

ANIM

indecipherable

0171-2004 actice. The modification produced in the quinolone nucleus by introducing a fluorine at the 6-position led to the discovery of the newer fluoroquinolones with enhanced antibacterial activities as compared to nalidixic acid. By now a great deal of preclinical and clinical experience has been obtained

網(wǎng)絡(luò)添麻煩

tangle

Endemic

領(lǐng)導(dǎo)權(quán)

Pharmacokinetics of Fluoroquinolones in Experimental Animals, agent but also influence significantly its antibacterial efficacy at the focus of infection. During the developmental process of an antimicrobial agent, infection models in experimental animals bridge the gap between the in vitro and clinical evaluation of an anti-infective agent. However, some res

GROG

Pharmacodynamics of Fluoroquinolones in Experimental Animals,harmacokinetics of fluoroquinolones in experimental animals is reviewed in Chap. 5. This chapter reviews the pharmacodynamics of these agents in animal infection models with infections induced by extracellular and intracellular pathogens. The discussion focuses not only on the efficacy of fluoroquin

Defraud

,Interaction of Quinolones with Host—Parasite Relationship,arasite relationship — commences by adherence of bacteria to and colonization of epithelial surfaces, followed by penetration into and dissemination within the macroorganism. Antibiosis interferes with these stages of infection.

軟弱

Microaneurysm

Toxicology and Safety Pharmacology of Quinolones,to give an overview of the toxicological profile of this class of compounds. Based on current knowledge, it appears that the pattern of preclinical adverse reactions is comparable for all quinolones, although there are some differences in both the incidence and the type of reaction induced by certai